Abstract
We report a patient with pyoderma gangrenosum successfully treated with intravenous immunoglobulin. He had previously been treated for 4 years with high-dose corticosteroids and had developed insulin-dependent diabetes mellitus. Multiple corticosteroid-sparing agents had failed or were contraindicated. He developed no adverse effects from intravenous immunoglobulin, which allowed reduction of his prednisone to 3 mg/day, and his ulcer has completely healed.
MeSH terms
-
Diabetes Mellitus, Type 1 / chemically induced
-
Diabetes Mellitus, Type 1 / complications
-
Drug Therapy, Combination
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / adverse effects
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use*
-
Immunologic Factors / therapeutic use*
-
Leg Ulcer / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Pyoderma Gangrenosum / drug therapy*
-
Pyoderma Gangrenosum / etiology
-
Treatment Outcome
Substances
-
Glucocorticoids
-
Immunoglobulins, Intravenous
-
Immunologic Factors